Kategorier: Adacolumn

20 September 2023 11:49

Otsuka and Astex announce that the European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia

LONDON, UK, and PLEASANTON, CA, USA, 19 September 2023 – Otsuka Pharmaceutical Europe Ltd. (Otsuka) and Astex Pharmaceuticals, Inc. (Astex) today announce that the European Commission (EC) has approved INAQOVI® (oral decitabine and cedazuridine) as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemothera

22 September 2022 14:06

Otsuka kondigt aan dat de EC Lupkynis®▼ (voclosporine) heeft goedgekeurd als eerste orale behandeling voor actieve lupus nefritis

LONDEN, VK, 20 september 2022 – Otsuka Pharmaceutical Europe Co. Ltd. heeft vandaag aangekondigd dat de Europese Commissie (EC) Lupkynis® (voclosporine) in combinatie met mycofenolaatmofetil heeft goedgekeurd voor de behandeling van volwassen patiënten met actieve klasse III, IV of V (inclusief gemengde klasse III/V en IV/V) lupus nefritis (LN). Het besluit van de Europese Commissie geldt voor all

20 September 2022 15:43

Otsuka tillkännager EU-kommissionens godkännande av Lupkynis®▼ (voklosporin) som första orala behandling för aktiv lupus nefrit

LONDON, STORBRITANNIEN, 20 september 2022 – Otsuka Pharmaceutical Europe Ltd. tillkännager idag att EU-kommissionen har godkänt Lupkynis® (voklosporin) i kombination med mykofenolatmofetil (MMF) för behandling av vuxna patienter med aktiv klass III, IV eller V (däribland blandad klass III/V och IV/V) lupus nefrit (LN). EU-kommissionens beslut gäller alla 27 medlemsländer inom EU samt Island, Norge

20 September 2022 15:35

Otsuka tillkännager EU-kommissionens godkännande av Lupkynis®▼ (voklosporin) som första orala behandling för aktiv lupus nefrit

Otsuka Pharma Scandinavia AB

Otsuka is a global healthcare company with the corporate philosophy: “Otsuka-people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, focusing on pharmaceutical
products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals, Otsuka is a leader in the challenging area of mental health and also has research programs in several under-addressed diseases including tuberculosis, a significant global public health issue.

Otsuka Europe employs around 550 people and focuses on psychiatric and neurologic disorders, infectious disease, nephrology, oncology, and digital medicines. Otsuka Pharma Scandinavia AB is an affiliate to Otsuka Pharmaceutical Europe Ltd., who is a part of Otsuka Pharmaceutical Company, Ltd., a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan.

The Otsuka group of companies employed 47,000 people worldwide with consolidated sales of approximately €12.4 billion and a spend of €1.67 billion on research and development in 2022. For further information on Otsuka, please visit www.otsuka.se.

NOR-NPR-2300003